Economic evaluation of critically ill adult CAR-T cell recipients—analysis from a healthcare payer perspective
In relation to the total costs of CAR-T-cell therapy (production of the CAR‑T product), therapy-associated complications have a relatively low impact on the costs and utilization of ICU resources.
Authors
- Nicolaus Martin Kröger (ORCID: https://orcid.org/0000-0001-5103-9966)
- Francis Ayuk
- Dominic Wichmann (ORCID: https://orcid.org/0000-0002-4334-7640)
- Kevin Roedl (ORCID: https://orcid.org/0000-0002-0721-9027)
- Panagiotis Karagiannis (ORCID: https://orcid.org/0000-0001-6459-7561)
- Sonja Essmann (ORCID: https://orcid.org/0000-0002-2669-7219)
- Markus Haar (ORCID: https://orcid.org/0000-0003-2461-5002)
- Paymon Ahmadi
- Stefan Kluge (ORCID: https://orcid.org/0000-0001-8391-3988)
- Sarosh Aamir
Institutions
- Universität Hamburg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
Publication Details
- Journal
- Medizinische Klinik - Intensivmedizin und Notfallmedizin
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1007/s00063-024-01230-z
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universitätsklinikum Hamburg-Eppendorf